Lineage Cell Therapeutics (LCTX) Misses Q2 EPS by 1c

Lineage Cell Therapeutics (NYSE: LCTX) reported Q2 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $4.15 million versus the consensus estimate of $3.68 million.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• Verizon to cut 3,000 jobs as it shifts stores to franchises
• Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease
• FingerMotion, Inc. (FNGR) Reports Q1 Loss of $0.03